Therapeutic use of H2O2-responsive anti-oxidant polymer nanoparticles for doxorubicin-induced cardiomyopathy

Biomaterials

Volumn 35, Issue 22, 2014, Pages 5944-5953

  Park, Seunggyu ^a   Yoon, Jooheung ^b   Bae, Soochan ^b   Park, Minhyung ^a   Kang, Changsun ^a   Ke, Qingen ^b   Lee, Dongwon ^a   Kang, Peter M ^a,b  

^a Chonbuk National University   (South Korea)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Anti oxidant; Doxorubicin; Heart failure; Hydrogen peroxide; Polyoxalate

Indexed keywords

CARDIOLOGY; CELL DEATH; HEART; HYDROGEN PEROXIDE; NANOPARTICLES; PEROXIDES; TOXICITY;

ANTI-INFLAMMATORIES; ANTIAPOPTOTIC PROPERTIES; DOXORUBICIN; HEART FAILURE; INTRAPERITONEAL INJECTIONS; POLY(ADP RIBOSE) POLYMERASE 1; POLYMER NANOPARTICLES; POLYOXALATE;

POLYMERS;

ANTIOXIDANT; CARDIOVASCULAR AGENT; CASPASE 3; DOXORUBICIN; HYDROGEN PEROXIDE; INDUCIBLE NITRIC OXIDE SYNTHASE; MONOCYTE CHEMOTACTIC PROTEIN 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; POLYOXALATE CONTAINING VANILLYL ALCOHOL; REACTIVE OXYGEN METABOLITE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; BENZYL ALCOHOL DERIVATIVE; NANOPARTICLE; OXALIC ACID; POLYMER; VANILLYL ALCOHOL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTICLE; CARDIOMYOPATHY; CARDIOTOXICITY; CONTROLLED STUDY; DRUG INDUCED DISEASE; ENZYME ACTIVATION; HEART FUNCTION; LIVER TOXICITY; MALE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURVIVAL RATE; TRANSTHORACIC ECHOCARDIOGRAPHY; ANIMAL; C57BL MOUSE; CARDIOMYOPATHIES; CHEMICALLY INDUCED; CHEMISTRY; METABOLISM;

MUS;

ANIMALS; ANTIOXIDANTS; BENZYL ALCOHOLS; CARDIOMYOPATHIES; DOXORUBICIN; HYDROGEN PEROXIDE; MALE; MICE; MICE, INBRED C57BL; NANOPARTICLES; OXALIC ACID; POLYMERS;

EID: 84899976443     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2014.03.084     Document Type: Article

References (44)

1. Bergh J., Jonsson P.E., Glimelius B., Nygren P. Asystematic overview of chemotherapy effects in breast cancer. Acta Oncol 2001, 40:253-281.
2. Blum R.H., Carter S.K. Adriamycin. A new anticancer drug with significant clinical activity. Ann Intern Med 1974, 80:249-259.
3. Tesch H., Diehl V., Lathan B., Hasenclever D., Sieber M., Ruffer U., et al. Moderate dose escalation for advanced stage Hodgkin's disease using the bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone scheme and adjuvant radiotherapy: a study of the German Hodgkin's Lymphoma Study Group. Blood 1998, 92:4560-4567.
4. She W., Luo K., Zhang C., Wang G., Geng Y., Li L., et al. The potential of self-assembled, pH-responsive nanoparticles of mPEGylated peptide dendron-doxorubicin conjugates for cancer therapy. Biomaterials 2013, 34:1613-1623.
5. Yang Y., Pan D., Luo K., Li L., Gu Z. Biodegradable and amphiphilic block copolymer-doxorubicin conjugate as polymeric nanoscale drug delivery vehicle for breast cancer therapy. Biomaterials 2013, 34:8430-8443.
6. She W., Li N., Luo K., Guo C., Wang G., Geng Y., et al. Dendronized heparin-doxorubicin conjugate based nanoparticle as pH-responsive drug delivery system for cancer therapy. Biomaterials 2013, 34:2252-2264.
7. Lefrak E.A., Pitha J., Rosenheim S., Gottlieb J.A. Aclinicopathologic analysis of adriamycin cardiotoxicity. Cancer 1973, 32:302-314.
8. Swain S.M., Whaley F.S., Ewer M.S. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 2003, 97:2869-2879.
9. Von Hoff D.D., Layard M.W., Basa P., Davis H.L., Von Hoff A.L., Rozencweig M., et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979, 91:710-717.
10. Mimnaugh E.G., Trush M.A., Ginsburg E., Gram T.E. Differential effects of anthracycline drugs on rat heart and liver microsomal reduced nicotinamide adenine dinucleotide phosphate-dependent lipid peroxidation. Cancer Res 1982, 42:3574-3582.
11. Takemura G., Fujiwara H. Doxorubicin-induced cardiomyopathy from the cardiotoxic mechanisms to management. Prog Cardiovas Dis 2007, 49:330-352.
12. Babson J.R., Abell N.S., Reed D.J. Protective role of the glutathione redox cycle against adriamycin-mediated toxicity in isolated hepatocytes. Biochem Pharmacol 1981, 30:2299-2304.
13. Kalivendi S.V., Kotamraju S., Zhao H., Joseph J., Kalyanaraman B. Doxorubicin-induced apoptosis is associated with increased transcription of endothelial nitric-oxide synthase. Effect of antiapoptotic antioxidants and calcium. JBiol Chem 2001, 276:47266-47276.
14. Wang S., Konorev E.A., Kotamraju S., Joseph J., Kalivendi S., Kalyanaraman B. Doxorubicin induces apoptosis in normal and tumor cells via distinctly different mechanisms. intermediacy of H(2)O(2)- and p53-dependent pathways. JBiol Chem 2004, 279:25535-25543.
15. Lee D., Bae S., Hong D., Lim H., Yoon J.H., Hwang O., et al. H2O2-responsive molecularly engineered polymer nanoparticles as ischemia/reperfusion-targeted nanotherapeutic agents. Sci Rep 2013, 3:2233.
16. Ko E., Jeong D., Kim J., Park S., Khang G., Lee D. Antioxidant polymeric prodrug microparticles as a therapeutic system for acute liver failure. Biomaterials 2014, 35:3095-3102.
17. Alonso M., Tamasdan C., Miller D.C., Newcomb E.W. Flavopiridol induces apoptosis in glioma cell lines independent of retinoblastoma and p53 tumor suppressor pathway alterations by a caspase-independent pathway. Mol Cancer Ther 2003, 2:139-150.
18. Li K., Sung R.Y., Huang W.Z., Yang M., Pong N.H., Lee S.M., et al. Thrombopoietin protects against invitro and invivo cardiotoxicity induced by doxorubicin. Circulation 2006, 113:2211-2220.
19. Chen W.-H., Xu X.-D., Jia H.-Z., Lei Q., Luo G.-F., Cheng S.-X., et al. Therapeutic nanomedicine based on dual-intelligent functionalized gold nanoparticles for cancer imaging and therapy invivo. Biomaterials 2013, 34:8798-8807.
20. Rothe G., Valet G. Flow cytometric analysis of respiratory burst activity in phagocytes with hydroethidine and 2',7'-dichlorofluorescin. JLeukoc Biol 1990, 47:440-448.
21. Arnoult D., Parone P., Martinou J.C., Antonsson B., Estaquier J., Ameisen J.C. Mitochondrial release of apoptosis-inducing factor occurs downstream of cytochrome c release in response to several proapoptotic stimuli. JCell Biol 2002, 159:923-929.
22. Bae S., Yalamarti B., Kang P.M. Role of caspase-independent apoptosis in cardiovascular diseases. Front Biosci 2008, 13:2495-2503.
23. Bahi N., Zhang J., Llovera M., Ballester M., Comella J.X., Sanchis D. Switch from caspase-dependent to caspase-independent death during heart development: essential role of endonuclease G in ischemia-induced DNA processing of differentiated cardiomyocytes. JBiol Chem 2006, 281:22943-22952.
24. Pacher P., Nagayama T., Mukhopadhyay P., Batkai S., Kass D.A. Measurement of cardiac function using pressure-volume conductance catheter technique in mice and rats. Nat Protoc 2008, 3:1422-1434.
25. Bae S., Siu P.M., Choudhury S., Ke Q., Choi J.H., Koh Y.Y., et al. Delayed activation of caspase-independent apoptosis during heart failure in transgenic mice overexpressing caspase inhibitor CrmA. Am J Physiol Heart Circ Physiol 2010, 299:H1374-H1381.
26. Suliman H.B., Carraway M.S., Ali A.S., Reynolds C.M., Welty-Wolf K.E., Piantadosi C.A. The CO/HO system reverses inhibition of mitochondrial biogenesis and prevents murine doxorubicin cardiomyopathy. JClin Iinvest 2007, 117:3730-3741.
27. Neilan T.G., Blake S.L., Ichinose F., Raher M.J., Buys E.S., Jassal D.S., et al. Disruption of nitric oxide synthase 3 protects against the cardiac injury, dysfunction, and mortality induced by doxorubicin. Circulation 2007, 116:506-514.
28. Mukhopadhyay P., Rajesh M., Batkai S., Kashiwaya Y., Hasko G., Liaudet L., et al. Role of superoxide, nitric oxide, and peroxynitrite in doxorubicin-induced cell death invivo and invitro. Am J Physiol Heart Circ Physiol 2009, 296:H1466-H1483.
29. Gilleron M., Marechal X., Montaigne D., Franczak J., Neviere R., Lancel S. NADPH oxidases participate to doxorubicin-induced cardiac myocyte apoptosis. Biochem Biophys Res Commun 2009, 388:727-731.
30. Miranda C.J., Makui H., Soares R.J., Bilodeau M., Mui J., Vali H., et al. Hfe deficiency increases susceptibility to cardiotoxicity and exacerbates changes in iron metabolism induced by doxorubicin. Blood 2003, 102:2574-2580.
31. Vedam K., Nishijima Y., Druhan L.J., Khan M., Moldovan N.I., Zweier J.L., et al. Role of heat shock factor-1 activation in the doxorubicin-induced heart failure in mice. Am J Physiol Heart Circ Physiol 2010, 298:H1832-H1841.
32. Ueno M., Kakinuma Y., Yuhki K., Murakoshi N., Iemitsu M., Miyauchi T., et al. Doxorubicin induces apoptosis by activation of caspase-3 in cultured cardiomyocytes invitro and rat cardiac ventricles invivo. JPharmacol Sci 2006, 101:151-158.
33. Simunek T., Sterba M., Popelova O., Adamcova M., Hrdina R., Gersl V. Anthracycline-induced cardiotoxicity: overview of studies examining the roles of oxidative stress and free cellular iron. Pharmacol Rep 2009, 61:154-171.
34. Shi R., Huang C.C., Aronstam R.S., Ercal N., Martin A., Huang Y.W. N-acetylcysteine amide decreases oxidative stress but not cell death induced by doxorubicin in H9c2 cardiomyocytes. BMC Pharmacol 2009, 9:7.
35. Berthiaume J.M., Oliveira P.J., Fariss M.W., Wallace K.B. Dietary vitamin E decreases doxorubicin-induced oxidative stress without preventing mitochondrial dysfunction. Cardiovas Toxicol 2005, 5:257-267.
36. Ito T., Muraoka S., Takahashi K., Fujio Y., Schaffer S.W., Azuma J. Beneficial effect of taurine treatment against doxorubicin-induced cardiotoxicity in mice. Adv Exp Med Biol 2009, 643:65-74.
37. Daosukho C., Chen Y., Noel T., Sompol P., Nithipongvanitch R., Velez J.M., et al. Phenylbutyrate, a histone deacetylase inhibitor, protects against Adriamycin-induced cardiac injury. Free Radic Biol Med 2007, 42:1818-1825.
38. Konishi M., Haraguchi G., Ohigashi H., Ishihara T., Saito K., Nakano Y., et al. Adiponectin protects against doxorubicin-induced cardiomyopathy by anti-apoptotic effects through AMPK up-regulation. Cardiovas Res 2011, 89:309-319.
39. Chatterjee K., Zhang J., Tao R., Honbo N., Karliner J.S. Vincristine attenuates doxorubicin cardiotoxicity. Biochem Biophys Res Commun 2008, 373:555-560.
40. Raskovic A., Stilinovic N., Kolarovic J., Vasovic V., Vukmirovic S., Mikov M. The protective effects of silymarin against doxorubicin-induced cardiotoxicity and hepatotoxicity in rats. Molecules 2011, 16:8601-8613.
41. Hensley M.L., Hagerty K.L., Kewalramani T., Green D.M., Meropol N.J., Wasserman T.H., et al. American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants. JClin Oncol 2009, 27:127-145.
42. Sartor O., Dineen M.K., Perez-Marreno R., Chu F.M., Carron G.J., Tyler R.C. An eight-month clinical study of LA-2575 30.0 mg: a new 4-month, subcutaneous delivery system for leuprolide acetate in the treatment of prostate cancer. Urology 2003, 62:319-323.
43. Farazuddin M., Alam M., Khan A.A., Khan N., Parvez S., Dutt G.U., et al. Efficacy of amoxicillin bearing microsphere formulation in treatment of Listeria monocytogenes infection in Swiss albino mice. JDrug Target 2010, 18:45-52.
44. Korin N., Kanapathipillai M., Matthews B.D., Crescente M., Brill A., Mammoto T., et al. Shear-activated nanotherapeutics for drug targeting to obstructed blood vessels. Science 2012, 337:738-742.